Clinical trials: Malaria,Falciparum
Malaria (Plasmodium Falciparum)
Controlled Human Malaria Infection by Mosquito Bites Using a Local Strain of Plasmodium Falciparum
The project aims to reproduce the malaria infection cycle using African mosquitoes, namely Anopheles gambiae and a local strain of Plasmodium parasites.
- Trial name
- BB-LaCHMI-01 (NCT07816497)
- Testing
- Controlled Human Malaria Infection
- Where
- Gabon
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Uncomplicated Plasmodium Falciparum Malaria
Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria
This study aimed to determine the efficacy, safety and tolerability of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in pediatric patients (6 months to < 18 years of…
- Trial name
- KALUMI (NCT04546633)
- Testing
- KAF156, LUM-SDF, Coartem
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Asymptomatic P.Falciparum Malaria
Artemisia Annua Infusion for the Treatment of Asymptomatic Plasmodium Falciparum Infection
The goal of this clinical trial is to determine whether Artemisia annua dried leaves, used as an infusion, can treat individuals with malaria parasites but no symptoms.
- Trial name
- ART-CT001 (NCT07819825)
- Testing
- Artemisia Annua Leaf, Centaurii herba
- Where
- Gabon
- Volunteers
- 20 people
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Uncomplicated Malaria
Treatment of Uncomplicated Malaria in Benin
Malaria is a life-threatening disease especially in small children. A high degree of Plasmodium falciparum resistance to chloroquine has already spread to South-Benin where this study is taking place.
- Trial name
- NCT00460369
- Testing
- sulfadoxine-pyrimethamine, artemether-lumefantrine, amodiaquine-artesunate coformulation
- Where
- Benin
- Volunteers
- 240 people
- Sponsor
- Institut de Recherche pour le Developpement
Malaria, Plasmodium Falciparum
A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21
This is a Phase Ib multi-stage Plasmodium falciparum malaria vaccine study to assess the safety and immunogenicity of the blood-stage vaccine candidate RH5.2 virus-like particle (VLP) in Matrix-MTM and the pre-erythrocytic stage…
- Trial name
- NCT05357560
- Testing
- Matrix-M with RH5.2 VLP and/or R21
- Where
- The Gambia
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Uncomplicated Plasmodium Falciparum Malaria
Test Efficacy Study on the Recommended Antimalarial Drugs in the Democratic Republic of the Congo
Malaria remains a public health concern, despite efforts that are invested in the disease control. The Democratic Republic of the Congo (DRC) is one of the most affected countries in Sub Saharan Africa.
- Trial name
- TES2022 (NCT06076213)
- Testing
- Artesunate-amodiaquine, Artemether-lumefantrine
- Where
- 7 sites in Democratic Republic of the Congo
- Volunteers
- 1,260 people
- Sponsor
- Ministry of Public Health, Democratic Republic of the Congo
Falciparum Malaria
Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria
In Afghanistan, studies over the past 15 years have shown a high degree of Plasmodium falciparum resistance to chloroquine (80%) and more recently an increasing degree of resistance to sulfadoxine-pyrimethamine monotherapy (12%).
- Trial name
- ASPF (NCT01115439)
- Testing
- artesunate plus sulfadoxine-pyrimethamine (AS+SP)
- Where
- 4 sites in Afghanistan
- Volunteers
- 100 people
- Sponsor
- University of Oxford
Falciparum Malaria
Study to Investigate the Induction of an Protective Immune Response to Malaria
The objective of the study is to induce a protective immune response against malaria in healthy human volunteers. The different parts of the immune response will then be studied.
- Trial name
- NCT00442377
- Testing
- exposure to malaria sporozoites
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Pneumonia, Bacterial, Viral Infection
Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia
Clinical pneumonia is a leading cause of pediatric hospitalization. The etiology is generally bacterial or viral. Prompt and optimal treatment of pneumonia is critical to reduce mortality.
- Conditions
- Pneumonia, Bacterial, Viral Infection, Clinical Pneumonia, Plasmodium Falciparum Malaria
- Trial name
- NCT03996967
- Where
- 3 sites in United States, Netherlands and 1 more
- Volunteers
- 837 people
- Sponsor
- Boston University
Healthy Volunteers
Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population
This study will test a new drug (MAM01) to find which doses are safe and could help prevent people from getting malaria for at least 4 months. The study will take place in parts of Africa where malaria is common.
- Trial name
- NCT06408857
- Testing
- MAM01 300 mg SC, MAM01 300 mg IM, MAM01 2000 mg IV
- Where
- 2 sites in Uganda
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Malaria,Falciparum, Malaria
Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities
This community-based cluster randomized controlled trial aims to evaluate the effectiveness of time-limited, community-wide mass drug administration (MDA) with dihydroartemisinin-piperaquine (DHA-PPQ) and single low-dose…
- Trial name
- NCT04864444
- Testing
- Dihydroartemisinin-piperaquine, Primaquine
- Where
- Senegal
- Volunteers
- 10,715 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Plasmodium Falciparum Malaria
A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S
The purpose of this study is to assess two types of new malaria vaccines in different combinations. The study will enable us to assess: 1. The ability of the vaccines to prevent malaria infection. 2.
- Trial name
- NCT02252640
- Testing
- RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01), ChAd63 ME-TRAP (5 x 10^10 vp)
- Where
- 4 sites in United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria,Falciparum
Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali
The purpose of this study is to compare the gametocytocidal and transmission reducing activity of artemether-lumefantrine (AL) with and without a single dose of 0.25mg/kg primaquine (PQ) and sulfadoxine-pyrimethamine with…
- Trial name
- NECTAR3 (NCT05081089)
- Testing
- Artemether-lumefantrine, Primaquine Phosphate, Sulphadoxine-pyrimethamine with amodiaquine
- Where
- Mali
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Clinical Performance Evaluation of Fyodor Urine Malaria Test (UMT)
The purpose of this study is to evaluate the clinical performance of the one-step Fyodor Urine Malaria Test (UMT), to determine its accuracy (sensitivity and specificity) for the diagnosis of Plasmodium falciparum malaria in…
- Trial name
- NCT01921413
- Testing
- Urine Malaria Test
- Where
- Nigeria
- Volunteers
- 1,893 people, healthy volunteers welcome
- Sponsor
- Fyodor Biotechnologies Inc
Malaria
Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults
Malaria has remained a major concern for the US military. During World War II, malaria was the leading cause of disease and non-battle injury with 500-700 men infected per day, resulting in 24,000 malaria-related casualties.(10)…
- Trial name
- NCT01540474
- Testing
- Group 1: 10 ug FMP012 with 2 ug GLA-SE, Group 2: 10 ug FMP012 with 5 ug GLA-SE, 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Plasmodium Falciparum Malaria
Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers
The objective of this study was to evaluate the safety of a candidate malaria vaccine (PfAMA-1) at 3 doses given at monthly intervals of 2 different dosages of AMA-1 (10 μg or 50 μg ) adjuvanted either with alum hydroxide or…
- Trial name
- NCT00730782
- Testing
- PfAMA-1-FVO[25-545]
- Where
- 2 sites in Netherlands
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- European Vaccine Initiative
Malaria
Dose Escalation PfSPZ-CVac
Background: People get malaria from bites from infected mosquitos. Researchers are studying a vaccine strategy. They will give people malaria parasites by injecting them with live infectious malaria parasites with antimalarial…
- Trial name
- NCT03083847
- Testing
- Chloroquine Phosphate, Pyrimethamine, Sanaria PfSPZ Challenge
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
A Study to Assess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of Administration
The purpose of this study is to assess the safety and immunogenicity of novel routes of administration of the candidate malaria vaccines ChAd63 encoding ME-TRAP and MVA encoding ME-TRAP.
- Trial name
- NCT03084289
- Testing
- ChAd63-METRAP, MVA ME-TRAP
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Malaria Vaccines
A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologicals' RTS, S/AS01E Malaria Vaccine in Young Children Across Sub-Saharan Africa
The RTS, S/AS01E vaccine was developed to protect children in sub-Saharan Africa from malaria as part of routine immunization programs. This study aims to check the vaccine's safety after it has been introduced.
- Trial name
- EPI-MAL-003 (NCT03855995)
- Testing
- Whole blood sample
- Where
- 6 sites in Ghana, Kenya and 1 more
- Volunteers
- 77,953 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Non-falciparum Malaria
Treatment of Non-falciparum Malaria
Patients with non-falciparum infection will be given artemether-lumefantrine for three days and will be followed up for 28 days. Besides efficacy and safety evaluations a substudy on immunology will be performed.
- Trial name
- NCT00725777
- Testing
- artemether-lumefantrine
- Where
- Gabon
- Volunteers
- 40 people
- Sponsor
- Albert Schweitzer Hospital